Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
Stable expression over 15 generations with rapid cell line development in just 3 months. Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) a
prkar1aa
Official Full Name
protein kinase, cAMP-dependent, regulatory, type I, alpha (tissue specific extinguisher 1) a
Organism
Danio rerio
Gene ID
494533
Background
Predicted to enable cAMP binding activity; cAMP-dependent protein kinase inhibitor activity; and protein kinase A catalytic subunit binding activity. Predicted to be involved in adenylate cyclase-activating G protein-coupled receptor signaling pathway. Predicted to act upstream of or within phosphorylation and regulation of protein phosphorylation. Predicted to be located in plasma membrane. Predicted to be part of cAMP-dependent protein kinase complex. Predicted to be active in cytosol. Is expressed in early embryonic cell; immature eye; neural tube; and somite. Human ortholog(s) of this gene implicated in Carney complex; acrodysostosis; and primary pigmented nodular adrenocortical disease 1. Orthologous to human PRKAR1A (protein kinase cAMP-dependent type I regulatory subunit alpha). [provided by Alliance of Genome Resources, Feb 2025]